Moffitt Cancer Center | Strategic Alliance Partners

August 09, 2023

Kedar Kirtane, MD, speaks on the unique mechanism of action of A2B530 and how the agent could represent a huge leap forward in the application of CAR T-cell agents for patients with solid tumors if the EVEREST-1 study proves to be positive.

August 07, 2023

Roger Li, MD, expands on the mechanism of action for the combination of CG0070 and pembrolizumab, and discusses the rationale for investigating the regimen's synergy in patients with non–muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guérin.

August 07, 2023

Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.

August 04, 2023

Amanda Bloomer, PhD, discusses the rationale for launching the ColoCare study, an investigation into the health-related quality of life outcomes of younger vs older adult patients with newly diagnosed colorectal cancer.

August 03, 2023

Catherine C. Coombs, MD, and Alexey Danilov, MD, PhD, moderate a discussion on the role and sequencing of BTK inhibitors, venetoclax-based regimens, and CAR T-cell therapy in mantle cell lymphoma and chronic lymphocytic leukemia.

July 31, 2023

Key opinion leaders reflect on data from the 2023 ASCO meeting and how it may impact the management of diffuse large B-cell lymphoma.

July 27, 2023

Heather Han, MD, discusses initial safety and efficacy results from the phase 2 NATASHA trial in patients with early-stage HER2-positive breast cancer.

July 24, 2023

Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.

July 20, 2023

Rami Komrokji, MD, shares the potential clinical implications of data from the phase 3 COMMANDS trial of luspatercept in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.

July 17, 2023

Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.

July 17, 2023

A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.

July 14, 2023

Rami Komrokji, MD, discusses the clinical implications of the phase 3 COMMANDS trial in patients with very low–, low-, or intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.

July 14, 2023

A broad view of the current treatment paradigm for relapsed/refractory follicular lymphoma and how the field has been evolving.

July 14, 2023

Experts Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, reflect on recent updates to the treatment guidelines for patients with follicular lymphoma.

July 10, 2023

Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

July 10, 2023

Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

July 06, 2023

George Simon, MD, FACP, FCCP, discusses findings from an FDA pooled analysis of PD-1/PD-L1 inhibitors with or without chemotherapy in patients with non–small cell lung cancer.

July 05, 2023

Andrew S. Brohl, MD, discusses the safety and immunologic responses with intratumoral administration of Idx-Hu2.0 in patients with advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma.

July 05, 2023

Danielle K. DePalo, MD, discusses findings from a study comparing first-line isolated limb infusion/perfusion vs immune checkpoint inhibitors and intratumoral therapy in patients with surgically unresectable melanoma in-transit metastases.

July 05, 2023

A treatment regimen consisting of pepinemab plus trastuzumab and a dendritic cell vaccine, followed by autologous CD4-positive T cells, is under investigation in a phase 1 trial in patients with metastatic HER2-positive breast cancer.